focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,756.00
Bid: 1,753.00
Ask: 1,754.00
Change: -19.00 (-1.07%)
Spread: 1.00 (0.057%)
Open: 1,770.00
High: 1,770.00
Low: 1,740.00
Prev. Close: 1,775.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Stocks End Up As Fed and BoJ Decisions Loom

Wed, 27th Apr 2016 15:56

LONDON (Alliance News) - UK shares ended higher Wednesday, with focus on the US Federal Reserve interest rate decision due later today, while investors will have to keep on their toes for the same by the Bank of Japan in the early hours of Thursday.

The FTSE 100 ended up 0.6%, or 35.39 points, at 6,319.91. The FTSE 250 ended up 0.8%, or 138.22 points, at 17,083.71, and the AIM-All Share fell 0.14 points to 729.08.

The Fed monetary policy decision is scheduled for 1900 BST. Economists overwhelmingly expect the central bank to leave its Federal Funds rate target unchanged, but a calmer global macroeconomic backdrop could mean the Fed hints at a rate rise at its next meeting in June.

FOREX.com analyst Fawad Razaqzada also expects the Fed not to announce changes to its monetary policy. However, Razaqzada said investors will scan the statement searching for clues on whether the Fed will hike rates in its next meeting.

"The dollar and other financial markets could...move sharply depending on the language the Federal Open Market Committee uses in the policy statement to describe the health of the world's largest economy, inflation outlook and the likely path of future interest rate changes," Razaqzada said. "This will have indirect impact on some commodities which are priced in the US dollar, such as gold and silver."

Brent oil touched a high of USD47.02 a barrel Wednesday, a level it hasn't seen since mid-November. The North Sea benchmark was adding to its Tuesday gains, when crude prices increased after the American Petroleum Institute reported a draw of nearly 1.1 million barrels in US oil inventories last week.

However, oil prices then retreated Wednesday after the US Energy Information Administration reported a 2 million-barrel climb in crude-oil supplies for the week ended April 22.

Brent was standing at USD46.12 a barrel at the London equities close, higher than the USD45.60 at the same time Tuesday. Meanwhile, gold was quoted at USD1,247.60 an ounce at the close, compared to the USD1,241.76 an ounce on Tuesday.

Stocks in New York were lower at the London equities close, with the Dow 30 down 0.1% and the S&P 500 down 0.2%.

The Nasdaq Composite was down 0.8%, hit by technology giant Apple's drop in profit in the second-quarter, hurt largely by a double-digit revenue decline that reflected weak iPhone sales. Apple reported its results Tuesday after the Wall Street close. Apple shares were down 5.6% at the London close.

In addition to the Fed this week is a Bank of Japan policy decision set for Thursday at 0400 BST. The Japanese central bank will conclude its two-day policy meeting, with analysts widely expecting it to announce a slew of measures to help weaken the yen.

"Given past policy behaviour, we therefore expect the BoJ's chairman Kuroda to be ready to surprise the markets again this year," said Maitland analyst Cebuan Bliss. "'Helicopter money', a consumption subsidy rather of fiscal policy nature, could become a frantic option, as Prime Minister Abe's reform policies have disappointed so far."

Helicopter money refers to a radical form of monetary policy that involves printing large sums of money and distributing it to the public in order to stimulate the economy, like a helicopter scattering euro notes to a crowd.

The UK economy grew at a slower pace, as expected, in the first quarter, preliminary estimates from the Office for National Statistics showed. Gross domestic product grew 0.4%, from a quarter ago, when it expanded 0.6%. This was in line with expectations.

Output increased in the dominant services sector by 0.6%. The other three main industrial groupings within the economy decreased, with production falling by 0.4%, construction output by 0.9% and agriculture by 0.1%.

On a yearly basis, UK GDP grew 2.1% in the first quarter, slightly faster than the expected growth of 2.0%.

Another report from the ONS showed the UK index of services rose 2.5% in February from last year, with the largest contribution coming from distribution, hotels and restaurants and business services and finance. Month-on-month, services output edged up 0.1%, the same pace of growth as in January.

The pound gyrated heavily before and after the economic data, with sterling reaching an intraday high of USD1.4621 prior and then declining to a low of USD1.4550 shortly afterwards. The pound stood at USD1.4544 at the London close compared to USD1.4590 at the close Tuesday.

The euro was quoted at USD1.1308 at the close, slightly lower than USD1.1310 on Tuesday.

In Paris, the CAC 40 index ended up 0.6%, and the DAX 30 in Frankfurt rose 0.4%.

On the London Stock Exchange, Worldpay Group ended up 4.3%, benefiting from an upgrade by UBS to Buy from Neutral. The Swiss bank said Worldpay's exposure to online transactions and significant investment in new value-added services will enable the company to outgrow its peers.

GlaxoSmithKline ended up 2.0% after the drugmaker pleased investors as it clarified its 2016 earnings guidance after an "encouraging" start to the year, implying higher earnings growth than previously indicated, as it continued to see benefits from its three part deal with Novartis AG in 2014.

GlaxoSmithKline's first quarter results beat expectations, helped by strong growth from its vaccines and consumer healthcare businesses, bolstered by the acquisitions it made from Novartis, which offset a small decline to its pharmaceuticals segment following the sale of its oncology business to the Swiss pharmaceutical firm.

Barclays ended up 0.5%, after an intense day for the stock following the lender's first-quarter earnings. The bank said the results showed a core business in rude health even as the bank saw a 25% drop in pretax profit. The stock opened higher, reaching 182.00 pence, its highest level since early-February. However, the shares declined since, closing at 174.80p.

Pretax profit fell to GBP793 million in the three months ended March 31, Barclays said, down from GBP1.06 billion the corresponding quarter a year earlier, with income net of insurance claims down 11% to GBP5.04 billion and credit impairment charges up 15% to GBP443 million. The results were ahead of analyst expectations, reflecting a strong performance in the bank's core business and resilience in its investment banking business.

Emerging-market-focused peer Standard Chartered fell 1.1%, among the worst blue-chip performers, having been downgraded to Sell from Hold by Deutsche Bank. The stock gave back only part of the gains it made Tuesday, when it added 9.8%, reaching its highest level in 2016, after its first-quarter loan impairment charges and capital strength proved better than the market had expected.

In the FTSE 250, Amec Foster Wheeler rose 3.7%, ending among the best performers. The oilfield services company said it has appointed Jonathan Lewis, who has held several senior roles at US giant Halliburton, as its new chief executive, as the company reported a drop in revenue in the first quarter of 2016.

Revenue in the quarter amounted to GBP1.30 billion, 1.5% lower than the GBP1.32 billion booked a year earlier. Revenue was also down 3.1% on a like-for-like basis compared to the previous year. The company's order book stood at GBP6.40 billion at the end of March, compared to GBP6.60 billion at the end of 2015, representing a 3.0% fall.

Societe Generale held a Buy recommendation on the company as the French bank believes this was "a 'normal' but relatively resilient performance in the current environment".

At the other end of the index, McCarthy & Stone dropped 6.1% after funds managed by Anchorage Capital, TPG Special Situations Partners, Goldman Sachs European Special Situations Group and Strategic Value Partners sold 85.0 million shares in the retirement housebuilder, increased from the 75.0 million they had initially planned to sell.

The gross proceeds from the sale to the selling investors were around GBP200.0 million. Following the sale, Anchorage holds a 7.6% stake, TPG a 3.9% stake, Goldman Sachs a 3.9% stake and Strategic Value Partners a 4.2% stake.

In the UK corporate calendar Thursday, Lloyds Banking Group, Taylor Wimpey, WPP, Schroders, Aggreko, Howden Joinery Group, Tullow Oil, Weir Group, Kaz Minerals, Berendsen, NCC Group and Synthomer issue trading statements. Air Partner, Oxford Biomedica, Harvey Nash Group, Camelia, GameAccount Network, U and I Group and Petropavlovsk release full-year results. Avocet Mining publishes a first-quarter production statement.

In the economic calendar, Japan's housing starts data are due at 0600 BST. The UK's nationwide housing prices are due at 0700 BST, while the eurozone's consumer confidence data are at 1000 BST. Germany's consumer price index is due at 1300 BST.

In the US, initial and continuing jobless claims and gross domestic product data are both due at 1330 BST, while the Energy Information Association natural gas storage data are due at 1530 BST.

By Daniel Ruiz; danielruiz@alliancenews.com

Copyright 2016 Alliance News Limited. All Rights Reserved.

More News
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 17:08

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies will urge a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more
22 Jan 2024 09:34

IN BRIEF: Oxford Nanopore appoints Keher to CFO as Cowper becomes COO

Oxford Nanopore Technologies - Oxford, England-based company specialising in nanopore DNA-sequencing - Appoints Nick Keher as chief financial officer and director, effective immediately. Keher will replace Tim Cowper as he moves into a new role as Oxford Nanopore's chief operating officer. The company says that Cowper has been performing the majority of COO duties for the past five years, and that he will lead the company's efforts to expand its international footprint. The company also says that new CFO Keher possesses "significant experience of financial leadership of complex, scientific businesses", having served in similar roles at Clinigen Group PLC, BenevolentAI SA, Royal Bank of Canada, Investec PLC and GSK PLC.

Read more
17 Jan 2024 09:38

UPDATE: GSK raises GBP978 million as cuts stake in Haleon to 4.2%

(Alliance News) - GSK PLC early Wednesday confirmed it agreed to sell 300 million shares in Haleon PLC, reducing its remaining stake in the consumer healthcare products spin-off to just 4.2%.

Read more
17 Jan 2024 08:05

GSK raises £978m through Haleon share sale

(Sharecast News) - GSK said on Wednesday that it has raised around £978m from the sale of shares in Haleon.

Read more
17 Jan 2024 07:46

LONDON BRIEFING: UK inflation surprises as unexpectedly rises to 4.0%

(Alliance News) - Stocks in London are called to open lower on Wednesday, following some hotter-than-expected consumer price data from the UK.

Read more
17 Jan 2024 07:31

GSK raises $1.24 bln from latest Haleon stake sale

Jan 17 (Reuters) - GSK has raised 978 million pounds ($1.24 billion) from a discounted sale of a stake in its spun-off consumer healthcare business Haleon, the British drugmaker said on Wednesday.

Read more
16 Jan 2024 17:04

GSK to sell GBP1 billion worth of Haleon shares as trims stake again

(Alliance News) - GSK PLC on Tuesday said it intends to sell around GBP1.00 billion worth of shares in Haleon PLC, as it continues to reduce its shareholding in the Weybridge, Surrey-based consumer healthcare spin-off.

Read more
16 Jan 2024 09:14

LONDON BROKER RATINGS: UBS raises GSK and cuts AstraZeneca

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
16 Jan 2024 08:15

UBS downgrades AstraZeneca to 'sell'

(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.

Read more
16 Jan 2024 07:37

LONDON BRIEFING: UK jobless rate sticks at 4.2% but pay growth slows

(Alliance News) - Stocks in London are called to open lower on Tuesday, following data showing that the UK jobless rate was unchanged at 4.2% as pay growth slowed.

Read more
15 Jan 2024 08:42

Zantac fallout unfairly weighing on GSK, says Shore Capital

(Sharecast News) - Shore Capital has raised its target price and maintained a positive stance on biopharma giant GSK, saying that worries about the potential cost of Zantac litigation are unfairly weighing on the stock.

Read more
10 Jan 2024 09:35

LONDON BROKER RATINGS: BofA cuts Ashtead; UBS likes 3i Group

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
10 Jan 2024 08:25

GSK says Nucala gets green light in China for asthma treatment

(Alliance News) - GSK PLC on Wednesday said Nucala has been approved in China for the treatment of severe asthma.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.